Characterization of soluble E-cadherin as a disease marker in gastric cancer patients
1998

Soluble E-cadherin as a Marker for Gastric Cancer

Sample size: 81 publication Evidence: moderate

Author Information

Author(s): J Gofuku, H Shiozaki, Y Doki, M Inoue, M Hirao, N Fukuchi, M Monden

Primary Institution: Osaka University Medical School

Hypothesis

Can serum soluble E-cadherin (S-ECD) serve as a reliable tumor marker for gastric cancer?

Conclusion

Serum S-ECD levels are significantly higher in gastric cancer patients compared to healthy individuals, suggesting its potential as a tumor marker.

Supporting Evidence

  • Serum S-ECD levels were significantly higher in gastric cancer patients (4735 ± 2310 ng/ml) than in healthy volunteers (2515 ± 744 ng/ml).
  • 67% of gastric cancer patients showed abnormally high serum S-ECD levels, which is significantly higher than other tumor markers like CEA and CA19-9.
  • Post-operative serum S-ECD levels decreased significantly after surgical removal of tumors.

Takeaway

Doctors found that a protein called soluble E-cadherin is much higher in the blood of people with stomach cancer than in healthy people, which could help in diagnosing the disease.

Methodology

Serum S-ECD levels were measured using a sandwich-type enzyme immunoassay kit, and E-cadherin expression was evaluated through immunohistochemistry.

Limitations

There was no significant correlation between serum S-ECD levels and clinicopathological factors such as tumor invasion or metastasis.

Participant Demographics

The study included 81 gastric cancer patients (60 men and 21 women) with a mean age of 63 years.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.0001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication